Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer (CRC), which could inject some much-needed sales growth into the product. The FDA has given ...

Just a few days after Biogen abandoned its tau-targeting Alzheimer's disease candidate gosuranemab, Bristol-Myers Squibb has opted into a rival drug, paying $80 million for rights to Prothena's PRX005 ...

We Tried the New Collection From Outdoor VoicesThe pieces we’d actually wear to work out and the ones that don’t quite pass muster.

A new digital atlas is the most comprehensive account of the Roman Empire’s terrestrial roads to date Brazil’s Lake Tefé reached 105.8 degrees Fahrenheit during the severe drought and heat wave Cool ...